Literature DB >> 11244035

Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.

A Moretta1, C Bottino, M Vitale, D Pende, C Cantoni, M C Mingari, R Biassoni, L Moretta.   

Abstract

Natural killer cells can discriminate between normal cells and cells that do not express adequate amounts of major histocompatibility complex (MHC) class I molecules. The discovery, both in mouse and in human, of MHC-specific inhibitory receptors clarified the molecular basis of this important NK cell function. However, the triggering receptors responsible for positive NK cell stimulation remained elusive until recently. Some of these receptors have now been identified in humans, thus shedding some light on the molecular mechanisms involved in NK cell activation during the process of natural cytotoxicity. Three novel, NK-specific, triggering surface molecules (NKp46, NKp30, and NKp44) have been identified. They represent the first members of a novel emerging group of receptors collectively termed natural cytotoxicity receptors (NCR). Monoclonal antibodies (mAbs) to NCR block to differing extents the NK-mediated lysis of various tumors. Moreover, lysis of certain tumors can be virtually abrogated by the simultaneous masking of the three NCRs. There is a coordinated surface expression of the three NCRs, their surface density varying in different individuals and also in the NK cells isolated from a given individual. A direct correlation exists between the surface density of NCR and the ability of NK cells to kill various tumors. NKp46 is the only NCR involved in human NK-mediated killing of murine target cells. Accordingly, a homologue of NKp46 has been detected in mouse. Molecular cloning of NCR revealed novel members of the Ig superfamily displaying a low degree of similarity to each other and to known human molecules. NCRs are coupled to different signal transducing adaptor proteins, including CD3 zeta, Fc epsilon RI gamma, and KARAP/DAP12. Another triggering NK receptor is NKG2D. It appears to play either a complementary or a synergistic role with NCRs. Thus, the triggering of NK cells in the process of tumor cell lysis may often depend on the concerted action of NCR and NKG2D. In some instances, however, it may uniquely depend upon the activity of NCR or NKG2D only. Strict NKG2D-dependency can be appreciated using clones that, in spite of their NCR(dull) phenotype, efficiently lyse certain epithelial tumors or leukemic cell lines. Other triggering surface molecules including 2B4 and the novel NKp80 appear to function as coreceptors rather than as true receptors. Indeed, they can induce natural cytotoxicity only when co-engaged with a triggering receptor. While an altered expression or function of NCR or NKG2D is being explored as a possible cause of immunological disorders, 2B4 dysfunction has already been associated with a severe form of immunodeficiency. Indeed, in patients with the X-linked lymphoproliferative disease, the inability to control Epstein-Barr virus infections may be consequent to a major dysfunction of 2B4 that exerts inhibitory instead of activating functions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11244035     DOI: 10.1146/annurev.immunol.19.1.197

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  519 in total

1.  Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.

Authors:  A Douglas Wilson; Andrew J Morgan
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 2.  In vivo immunogenetics: from MIC to RAET1 loci.

Authors:  Mirjana Radosavljevic; Seiamak Bahram
Journal:  Immunogenetics       Date:  2003-03-20       Impact factor: 2.846

3.  NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease.

Authors:  Nobuyoshi Hanaoka; Bana Jabri; Zhenpeng Dai; Cezary Ciszewski; Anne M Stevens; Cassian Yee; Hideki Nakakuma; Thomas Spies; Veronika Groh
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

Review 4.  Cell surface signaling molecules in the control of immune responses: a tide model.

Authors:  Yuwen Zhu; Sheng Yao; Lieping Chen
Journal:  Immunity       Date:  2011-04-22       Impact factor: 31.745

Review 5.  Myeloid suppressor cells and immune modulation in lung cancer.

Authors:  Minu K Srivastava; Åsa Andersson; Li Zhu; Marni Harris-White; Jay M Lee; Steven Dubinett; Sherven Sharma
Journal:  Immunotherapy       Date:  2012-03       Impact factor: 4.196

6.  Identification of HLA-E-specific alloreactive T lymphocytes: a cell subset that undergoes preferential expansion in mixed lymphocyte culture and displays a broad cytolytic activity against allogeneic cells.

Authors:  Chiara Romagnani; Gabriella Pietra; Michela Falco; Enrico Millo; Paola Mazzarino; Roberto Biassoni; Alessandro Moretta; Lorenzo Moretta; Maria Cristina Mingari
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-07       Impact factor: 11.205

Review 7.  Unravelling natural killer cell function: triggering and inhibitory human NK receptors.

Authors:  Lorenzo Moretta; Alessandro Moretta
Journal:  EMBO J       Date:  2003-12-18       Impact factor: 11.598

Review 8.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

9.  Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation.

Authors:  Junli Yu; Jeffrey M Venstrom; Xiao-Rong Liu; James Pring; Reenat S Hasan; Richard J O'Reilly; Katharine C Hsu
Journal:  Blood       Date:  2009-01-28       Impact factor: 22.113

10.  Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells.

Authors:  Roberta Castriconi; Claudia Cantoni; Mariella Della Chiesa; Massimo Vitale; Emanuela Marcenaro; Romana Conte; Roberto Biassoni; Cristina Bottino; Lorenzo Moretta; Alessandro Moretta
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.